16 September 2026 editorial review · Trial
Verapamil to preserve beta-cell function in newly diagnosed type 1 diabetes (Ver-A-T1D): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT04545151; COMPLETED; updated 2026-05-20; enrollment 136 (ACTUAL); results not posted.
Endpoint comparison: Area under the stimulated C-peptide response curve (At 12 months).
Sources for this record: NCT04545151: study record (registry); EASD: Ver-A-T1D conference results, September 2025 (conference); Ver-A-T1D randomized trial protocol (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.
Selected cell-therapy and adjunct trial review — 16 September 2026
Outcome and correction: Identified this as European Ver-A-T1D, not earlier US studies. Primary endpoint not met; per-protocol result cannot rescue it. Conference provenance explicit; investigator explanation attributed; broad safety claim removed.
Primary sources checked: Protocol; EASD September 2025 primary society release; Registry NCT04545151.
Limits: Release says no full paper available at presentation; full outcome publication not identified in this review. Exact P=.06/.034 removed because directly accessible society release describes significance without these values. Direct EurekAlert fetch returned 403, but web search returned the society release text.